Patient and donor characteristics
| No. of patients | 315 |
| Dates of transplantation | March 1995-December 2000 |
| Mean follow-up, mo (range) | 18 (0.3-70) |
| Median age, y (range) | 42 (16-63) |
| Diagnosis (%) | |
| AML/ALL/MDS | 174 (55) |
| CML CP1 | 71 (23) |
| NHL/CLL/MM | 61 (19) |
| Others | 9 (3) |
| Phase of disease (%) | |
| Early | 208 (66) |
| Advanced | 107 (34) |
| Sex (%) | |
| F to M | 74 (24) |
| M to M | 98 (31) |
| F to F | 71 (22) |
| M to F | 72 (23) |
| Cytomegalovirus serology (%) | |
| D− and R− | 29 (9) |
| D+ and/or R+ | 268 (85) |
| D or R NA | 18 (6) |
| Myeloablative regimen (%) | |
| TBI based | 172 (55) |
| Bu based | 143 (45) |
| GVHD prophylaxis (%) | |
| CsA + PDN or MTX | 201 (64) |
| CsA | 108 (34) |
| None | 6 (2) |
| Median cell content of the graft, × 106/kg (range) | |
| CD34+ cells | 4 (0.6-15) |
| CD3+ cells | 0.15 (0-3) |
| Cryopreservation (%) | 100 (32) |
| No. of patients | 315 |
| Dates of transplantation | March 1995-December 2000 |
| Mean follow-up, mo (range) | 18 (0.3-70) |
| Median age, y (range) | 42 (16-63) |
| Diagnosis (%) | |
| AML/ALL/MDS | 174 (55) |
| CML CP1 | 71 (23) |
| NHL/CLL/MM | 61 (19) |
| Others | 9 (3) |
| Phase of disease (%) | |
| Early | 208 (66) |
| Advanced | 107 (34) |
| Sex (%) | |
| F to M | 74 (24) |
| M to M | 98 (31) |
| F to F | 71 (22) |
| M to F | 72 (23) |
| Cytomegalovirus serology (%) | |
| D− and R− | 29 (9) |
| D+ and/or R+ | 268 (85) |
| D or R NA | 18 (6) |
| Myeloablative regimen (%) | |
| TBI based | 172 (55) |
| Bu based | 143 (45) |
| GVHD prophylaxis (%) | |
| CsA + PDN or MTX | 201 (64) |
| CsA | 108 (34) |
| None | 6 (2) |
| Median cell content of the graft, × 106/kg (range) | |
| CD34+ cells | 4 (0.6-15) |
| CD3+ cells | 0.15 (0-3) |
| Cryopreservation (%) | 100 (32) |
AML indicates acute myeloblastic leukemia; ALL, acute lymphoblastic leukemia; MDS, myelodysplastic syndrome; CML, chronic myeloid leukemia; CP, chronic phase; NHL, non-Hodgkin lymphoma; CLL, chronic lymphocytic leukemia; MM, multiple myeloma; D, donor; R, recipient; NA, not available; TBI, total body irradiation; Bu, busulfan; CsA, cyclosporine A; PDN, prednisone; and MTX, methotrexate.